BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Uroplasty, Inc. (UPI) Announces Urgent® PC Presentations at 2012 Western Section American Urological Association Meeting


10/9/2012 12:29:54 PM

MINNEAPOLIS, Oct. 9, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that at the October 7-10, 2012 Annual Meeting of the Western Section of the American Urological Association in Waikoloa, HI, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System.

Dr. Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI will present:

  • "Percutaneous Tibial Nerve Stimulation (PTNS) for the Treatment of Overactive Bladder Syndrome: Final 36-Month Results of the STEP Study" and
  • "Clinical Insights into Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder Syndrome: Secondary Analysis of the SUmiT Trial."

"We are pleased to have the 3-year STEP Study data presented for the first time," said David Kaysen, President and CEO of Uroplasty. "Dr. Kenneth Peters has been the lead investigator on this and previous clinical studies that established the safety and effectiveness of PTNS using the Urgent PC Neuromodulation System. This multi-center study demonstrated that patients, who respond to the initial 12 weeks of Urgent PC therapy, sustained their symptom improvement over 3 years.

"The SUmiT Trial originally proved that PTNS efficacy is superior to a validated sham procedure. Dr. Peters will present results of further data analysis of the SUmiT Trial which reiterate that PTNS is an effective treatment for patients with OAB," continued Mr. Kaysen.

"The safety and efficacy of PTNS was also reinforced by the recently published AUA Guidelines Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults which include PTNS as an essential part of the OAB algorithm of care," concluded Mr. Kaysen.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

EVC Group

Doug Sherk/Jenifer Kirtland (Investors),

415.568.9349

Chris Gale (Media), 646.201.5431

SOURCE Uroplasty, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES